leukaemia (SD) Flashcards

1
Q

Sx of leukameia

A

pallor
lethargy
pharyngitis
recurrent infections
easy bruising
pyrexia
night sweats
bone pain
flu-like sx
lymphadenopathy
splenomegaly
hepatomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

acute vs chronic

A

ACUTE
- fast growing
- can progress quickly without Tx
- cells multiply before any immune function has devleoped
- more common in young children
- sudden onset
- develops in weeks/months
- variable WBC count

CHRONIC
- slow growing
- cells have immature, limited immune function
- middle aged/elderly
- insidious
- develops over years
- high WBC count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

3 ways to classify leukaemia

A
  1. morphology
  2. immunophenotype
  3. genotype
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

difference between leukaemia and lymphoma

A

leukaemia = cancer of blood cells, starts in bone marrow

lymphoma = cancer of lymphatic system, starts in lymph nodes or spleen and SPREADS to bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is immunophenotyping?

A

used to ID CD proteins on cell surface which are used as markers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

CD marker of B cells

A

CD19
CD20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

risk factors for ALL

A

radiation, pesticides, viruses (EBV, HIV)

inherited syndromes (Down syndrome, Fanconi anemia, Bloom syndrome, ataxia telangiectasia and Nijmegen breakdown syndrome)

rase/ethnicity - more common in Caucasians

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is ALL

A

acute lymphoblastic leukaemia

neoplasms of precursor B and T cells, called lymphocytes

accumulation of lymphoblasts in bone marrow and peripheral blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How to immunophenotype?

A

flow cytometry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Are B or T cells most affected?

A

B cells (85%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how to differentiate betwen leukaemia and lymphoma

A

leukaemia if >25% bone marrow replaced by malignant cells

lymphoma if large lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

peak age of ALL incidence

A

3-7 years

rises again >40yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

investigations for ALL

A
  • FBC
  • blood film
  • bone marrow
  • immunophenotype
  • immunoglobulin and TCR genes
  • molecular genetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

bone marrow findings in investigations for ALL

A

hypercellular

with >20% blast cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

FBC for ALL

A
  • normochromic normocytic anaemia (normal sized RBC, normal Hb content)
  • neutropenia
  • thrombocytopenia
  • WBC count can be increased/normal/decreased
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

neutropenia

A

low neutrophil count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

thrombocytopenia

A

low platelet count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are blast cells?

A

large lymphocytes (huge WBCs)

morphology similar to myeoblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

pathogenesis of ALL

A
  1. first mutation occurs in the foetus in early lymphoid progenitor cells
  • cells continue to undergo alterations in bone marrow, forming lymphoblasts and prolymphocytes
  • germline mutation in <5% of cases
  1. 2nd genetic event occurs in childhood
  • could be associated with childhood infection and exposures (ionising radiation)
  • may be promoted through abnormal response to a common infection esp in under exposed infants
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

genetics in ALL

A
  • gene variability
  • chromosomal alterations - most common genetic driver
  • chimeric proteins
21
Q

What is aneuploidy?

A

gain or loss of whole chromosomes

22
Q

types of aneuploidy

A

hyperdiploid = >50 chromosomes, good prognosis

hypodiploid = <44 chromosomes, poor prognosis

23
Q

most common genetic driver for ALL

A

chromosomal abnormalities

24
Q

example of a chromosomal translocation

A

ETV6-RUNX1

25
What do chromosomal translocations do?
they create fusion genes that drive oncogenesis
26
How to detect chromosonal abnormalities?
FISH fluorescence in situ hybridisation
27
most common fusion gene in B-ALL
ETV6-RUNX1
28
ETV6-RUNX1 fusion gene
ETV6 = recruits transcriptional repressors RUNX1 = regulates transcription during haematopoiesis fusion gene leads to transcriptional silencing of RUNX1 targets and deregulation of haematopoieis not sufficient to drive leukaemia alone
29
BCR gene
breakpoint cluster region
30
What is the Philadelphia chromosome?
fusion of BCR and ABL1 genes onto the chromosome of each other ABL-1 is a - proto-oncogene - (non receptor) tyrosine kinase - roles in cell proliferation, survival or death and migration - activity limited by protein domain encoded by exon 1 fusion leads to loss of exon 1 and turns ABL into an oncogene
31
How does BCR-ABL1/Philadelphia positive cause leukaemia?
activates tyrosine kinase signalling through activation of: - Jak-Stat - MAPK causes cell growth, migration, differentiation inhibits apoptosis mechanisms - p53, inhibits caspsases
32
What is used first line to treat philadelphia positive ALL?
TKIs - imatinib
33
Treatment for imatinib resistance (in Ph+ ALL)?
alternate TKIs - dasatinib - ponatinib
34
How does methotrexate work?
it blocks pyrimidine/purine biosynthetic pathway and the proliferation of B cells by interfering with DNA synthesis, repair and replication suppresses the immune system
35
Tx for ALL relapse?
Rituximab
36
Rituximab MOA
* binds to cell surface protein CD20 on B cells * anti-CD20 B-cell depleter * mostly specific to B cells, some T cells * 3 MOA: 1. antibody dependent cell mediated toxicity via Fc region 2. complement mediated cell lysis 3. induction of apoptosis * depletes CD20+ B cells by binding to the CD20 antigen expressed on the B cell suraface * blockade of CD20 leads to B cell death via apoptosis and lysis
37
Repeated Tx of Rituximab?
patients progress after approx 36 months ans need repeat treatment
38
Other cancers that Rituximab is used in?
lymphoma
39
response rate of Rituximab
80%
40
What is CD20?
a cell marker on B cells during B cell differentiation
41
What is CD19?
cell marker on B cells plays a role in maintaining the balance between humoral, antigen-induced response and tolerance induction Tx target
42
What does PD-L1 do?
prevents tumour cells from 'evading' the immune system
43
Therapy to target CD19?
Blinatumomab
44
Therapy to target CD20?
Rituximab
45
Blinatumomab
tatgets CD19 BiTE - bispecific T cell engaging antibodies one part of the drug binds to CD3 on T cell 2nd part on drug binds to CD19 on the B cell (target cell) BiTE directs T cells to the B cell and assists T cell activaiton
46
BiTE therapy?
bi-specific T cell engaging antibodies
47
What is CAR-T cell therapy?
chimeric antigen receptor T cells T cells removed from patients own blood genitically engineered T cells that target CD19 B cells
48
What is prognosis of ALL determined by?
cytogenetic abnormality causing the disease (ETV6-RUNX1, hypodiploid, hyperdiploid, BCR-ABL all good prognosis)
49
Repeated Tx of Rituximab?
patients progress after approx 36 months ans need repeat treatment